Read the trial regimen with its result
STEP 1 enrolled 1,961 adults without diabetes and compared once-weekly subcutaneous semaglutide 2.4 mg with placebo over sixty-eight weeks, alongside lifestyle intervention. Mean body-weight change was -14.9% with semaglutide and -2.4% with placebo.
SURMOUNT-1 enrolled 2,539 adults without diabetes and tested once-weekly tirzepatide 5 mg, 10 mg and 15 mg against placebo over seventy-two weeks. The reported mean changes were -15.0%, -19.5% and -20.9%, respectively, compared with -3.1% for placebo.
Sources: PMID 33567185 · PMID 35658024
A cross-trial comparison has two sets of methods
Putting the largest percentage from one trial next to a percentage from another trial leaves out the comparison conditions. These studies used separate populations, treatment groups and follow-up periods. They do not become a head-to-head randomized trial when displayed beside one another.
The study table below retains the regimen and observation period for each result. A later direct comparison belongs in its own record with its own population and methods.
Sources: PMID 33567185 · PMID 35658024
A vial quantity is different from a weekly dose
The product’s listed vial quantity describes the preparation. The weekly administered amount and its escalation schedule describe the regimen. The trial follow-up period is also different from a purchasing or refill period.
Connecting these fields makes the ingredient research useful at the product level while preserving the distinction between a trial average and an individual person’s eventual outcome.
The formulation network
Each row connects a current product to the ingredient research behind its listed formulation.
Read the source studies
Research synthesis by HealthRX.com, October 5, 2026. The cited sources and linked ingredient pages describe the scope of this comparison.